Forest Labs to Present Trial Results on Cariprazine at ACNP Annual Meeting
Forest Laboratories, Inc. (NYSE: FRX) today announced it will be presenting data on cariprazine at the American College of Neuropsychopharmacology Annual Meeting scheduled December 2-6, 2012 in Hollywood, FL. Forest Laboratories, Inc recently submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for cariprazine for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with Bipolar I disorder.
The cariprazine results will be announced in 3 poster presentations:
* Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: A Phase III, International, Randomized, Double-blind, Placebo-controlled Trial (Poster 9: Wednesday, December 5 from 5:30 pm - 7:30 pm EST) * Cariprazine Exhibits Dopamine D Receptor-Dependent Antidepressant-Like Activity in the Chronic Unpredictable Stress Model of Anhedonia (Poster 12: Monday, December 3 from 5:30 pm - 7:30 pm EST) * Effects of Chronic Cariprazine Administration on Serotonin and Glutamate Receptor Subtypes (Poster 161: Monday, December 3 from 5:30 pm - 7:30 pm EST)
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.